Back to School: How biopharma can reboot drug development. Access exclusive analysis here

La Jolla Pharma to proceed with Phase III

Following a meeting with the FDA, LJPC has decided to conduct a Phase III trial of its LJP 394

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE